Matrix metalloproteinase-9 and autoimmune diseases

被引:263
作者
Ram, Maya
Sherer, Yaniv
Shoenfeld, Yehuda [1 ]
机构
[1] Chaim Sheba Med Ctr, Dept Med B, Sackler Fac Med, IL-52621 Tel Hashomer, Israel
[2] Chaim Sheba Med Ctr, Ctr Autoimmune Dis, Sackler Fac Med, IL-52621 Tel Hashomer, Israel
关键词
systemic lupus erythematosus; Sjogren's syndrome; systemic sclerosis; rheumatoid arthritis; multiple sclerosis; polymyositis; atherosclerosis; matrix; metalloproteinase-9;
D O I
10.1007/s10875-006-9022-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Matrix metalloproteinases (also named matrixin or MMPs) are a major group of enzymes that regulate cell-matrix composition by using zinc for their proteolytic activities. They are essential for various normal biological processes such as embryonic development, morphogenesis, reproduction tissue resorption, and remodeling. Metalloproteinases also play a role in pathological processes including inflammation, arthritis, cardiovascular diseases, pulmonary diseases and cancer. Herein we review the involvement of MMP-9 in a variety of autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, systemic sclerosis, rheumatoid arthritis, multiple sclerosis, polymyositis and atherosclerosis. MMP-9 plays either a primary or secondary role in each one of those autoimmune diseases by its up or down-regulation. It is not expressed constantly but rather is induced or suppressed by many regulating molecules. This feature of MMP-9 along with its involvement in disease pathogenesis turns it into a target for therapy of autoimmune diseases.
引用
收藏
页码:299 / 307
页数:9
相关论文
共 34 条
[1]   Hydrocortisone suppresses intranuclear activator-protein-1 (AP-1) binding activity in mononuclear cells and plasma matrix metalloproteinase 2 and 9 (MMP-2 and MMP-9) [J].
Aljada, A ;
Ghanim, H ;
Mohanty, P ;
Hofmeyer, D ;
Tripathy, D ;
Dandona, P .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (12) :5988-5991
[2]   Regulation of matrix metalloproteinases: An overview [J].
Chakraborti, S ;
Mandal, M ;
Das, S ;
Mandal, A ;
Chakraborti, T .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 2003, 253 (1-2) :269-285
[3]  
Chen F, 2005, INT J MOL MED, V15, P57
[4]   Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies [J].
Choi, YC ;
Dalakas, MC .
NEUROLOGY, 2000, 54 (01) :65-71
[5]   Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus [J].
Faber-Elmann, A ;
Sthoeger, Z ;
Tcherniack, A ;
Dayan, M ;
Mozes, E .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 127 (02) :393-398
[6]   Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: A potentially useful laboratory marker [J].
Gruber, BL ;
Sorbi, D ;
French, DL ;
Marchese, RRJ ;
Nuovo, GJ ;
Kew, RR ;
Arbeit, LA .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1996, 78 (02) :161-171
[7]   A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: Saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels [J].
Hanemaaijer, R ;
Visser, H ;
Konttinen, YT ;
Koolwijk, P ;
Verheijen, JH .
MATRIX BIOLOGY, 1998, 17 (8-9) :657-665
[8]  
Jiang X, 2004, CHINESE MED J-PEKING, V117, P1825
[9]   Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases [J].
Kieseier, BC ;
Archelos, JJ ;
Hartung, HP .
ARCHIVES OF NEUROLOGY, 2004, 61 (06) :929-932
[10]   Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis [J].
Kieseier, BC ;
Kiefer, R ;
Clements, JM ;
Miller, K ;
Wells, GMA ;
Schweitzer, T ;
Gearing, AJH ;
Hartung, HP .
BRAIN, 1998, 121 :159-166